Latest News and Press Releases

Kailera Therapeutics appoints 30-year biopharma industry veteran Frank Clyburn, Jr to its Board of Directors

Hengrui Pharma and Kailera today announced an oral presentation of HRS9531 Phase 3 data at ObesityWeek® 2025, the annual meeting of the Obesity Society.

Kailera Therapeutics announced a $600M Series B financing led by new investor Bain Capital Private Equity to support its late-stage obesity portfolio.

Kailera Therapeutics announced participation in upcoming investor conferences.

Hengrui and Kailera announced positive topline data from Hengrui’s Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist, in obesity.

Hengrui Pharma and Kailera today announced the presentation of six abstracts at the 85th Scientific Sessions of the American Diabetes Association (ADA).

Kailera Therapeutics today announced the appointments of Adam Koppel and Christopher Hite to its Board of Directors.

Kailera Therapeutics today announced the appointment of Jamie Coleman, former U.S. Brand Leader for Zepbound, as Chief Commercial Officer.

Kailera and Hengrui Pharma announced positive topline data from the 8 mg dose of Hengrui’s Phase 2 clinical trial of HRS9531, a GLP-1/GIP dual agonist.

Kailera Therapeutics today announced the appointment of Laurie Stelzer as Chief Financial Officer.